<DOC>
	<DOCNO>NCT01782222</DOCNO>
	<brief_summary>This trial conduct assess effect Rotigotine Placebo improvement Apathy motor symptom subject early-stage advanced stage idiopathic Parkinson´s Disease .</brief_summary>
	<brief_title>Trial Evaluate The Efficacy Of Rotigotine Parkinson 's Disease-Associated Motor Symptoms And Apathy</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>Patients early advance idiopathic Parkinson 's Disease Patients advance idiopathic Parkinson 's Disease : intake Levodopa stable dose least 200 mg/day Unsatisfactory control Parkinson 's Disease motor symptom current treatment Patients experience Apathy associate Parkinson 's Disease Hoehn Yahr stage score I IV MiniMental State Examination score ≥ 25 If antidepressant drug take , dose must stable Therapy Dopamine agonist Discontinuation pervious therapy dopamine agonist adequate length treatment , adequate dose , due lack efficacy Any medical psychiatric condition jeopardizes / compromise patient 's ability participation Patient receive Neuroleptics , Dopamine release substance , Dopamine modulating substance , AlphaMethyldopa , Metoclopramide , MAOA inhibitor , Budipine , Tolcapone Electroconvulsive therapy Patient current/anticipated psychotherapy behavior therapy history deep brain stimulation history suicide attempt suicidal ideation impulse control disorder severe Depression</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Parkinson 's Disease</keyword>
	<keyword>Rotigotine</keyword>
	<keyword>Apathy</keyword>
	<keyword>Nonmotor</keyword>
	<keyword>Motor</keyword>
	<keyword>Neupro</keyword>
</DOC>